QCLS Q/C TECHNOLOGIES, INC.: institutional ownership and insider trading
24 funds reported holding $3.09M of Q/C TECHNOLOGIES, INC. in their latest 13F filings; in Q2 2026 funds net bought $433K, with 6 new positions and 2 funds selling out; over the last 12 months insiders bought $5.52K and sold $0 on the open market.
QCLS revenue and earnings
- Quarter ended Jun 30, 2026: revenue n/a, net income −$6.62M, EPS -0.79
- Quarter ended Mar 31, 2026: revenue n/a, net income −$1.24M, EPS -0.19
- Quarter ended Dec 31, 2025: revenue n/a, net income −$5.89M, EPS 45.30
- Quarter ended Sep 30, 2025: revenue n/a, net income −$2.81M, EPS -2.50
Largest institutional holders of QCLS
- Quinn Opportunity Partners LLC — $480K
- VANGUARD CAPITAL MANAGEMENT LLC — $449K
- JANE STREET GROUP, LLC — $340K
- GEODE CAPITAL MANAGEMENT, LLC — $276K
- UBS Group AG (UBS) — $230K
- BALYASNY ASSET MANAGEMENT L.P. — $225K
- VANGUARD GROUP INC — $212K
- HRT FINANCIAL LP — $196K
- ADAR1 Capital Management, LLC — $195K
- VANGUARD FIDUCIARY TRUST CO — $168K
Recent QCLS insider trades
- Mar 30, 2026: Voss Chelsea Sierra bought 1,753 shares ($5.52K)
5%+ owners
- PharmaCyte Biotech, Inc.: 74.0% (Schedule 13D/A, filed Nov 18, 2025)